Universities in China’s Greater Bay Area have developed a recombinant receptor-binding domain (RBD) protein vaccine candidate that has shown promise against COVID-19, researchers said Monday at a press conference in Hong Kong. The vaccine can induce neutralizing activity after seven days with one dose, but more animal studies are now underway to test its durability.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Biocryst, Calidi, Cerecor, GW, Janssen, Morphosys, Novartis, Polypid, Roche, Sonoran, Tyme, Vanda.
HONG KONG – Singapore is Biofourmis Inc.’s latest destination for its Biovitals Sentinel platform to remotely monitor COVID-19 patients, with the country’s Ministry of Health (MOH) becoming the company’s latest customer.
Keeping you up to date on recent developments in neurology, including: Quanterix biomarker technology used to measure neuronal injury in COVID-19 patients; AI could speed up and improve Alzheimer's diagnosis; Mental fatigue of MS linked to inefficient recruitment of neural resources.